A pair of scientists from the University of Arizona and the University of California, Irvine, has formed a company to bring to market a colon cancer chemopreventive that combines an existing drug used to treat African sleeping sickness and a common non-steroidal anti-inflammatory.

The company, Cancer Prevention Therapeutics, is putting the final touches on an agreement with the schools to license the intellectual property surrounding the preventive, one of the co-founders said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.